Shares of British pharmaceutical giant, GlaxoSmithKline (GSK.US) more than 5% today amid $2.2 billion settlement deal in US Zantac lawsuits, caused by 'cancer-casuing' concerns. The deal will resolve 93% (almost 80,000) of US lawsuits. The company will recognize this loss in Q3 results, this year. All the settlements are expected to be implemented by the end of the first half of 2025. GSK confirmed also another $70 million paid to resolve the Zantac so-called qui tam complaint previously filed by Valisure. This agreement is pending final approval from the Department of Justice. Investors positively react to this news, improving 'uncertainty' about Zantac case.

Source: xStation5
DE40: Europan market still under pressure of weak industry and political turmoil
Daily summary: US100 surges almost 1% 📈Crypto and precious metals on the rise
Stock of the Month: Will Meta win the AI race?
AMD rises on the wave of the OpenAI deal. Pre-market trading shows a 25% increase in shares.